Last $7.39 USD
Change Today +0.07 / 0.96%
Volume 98.3K
OHRP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

ohr pharmaceutical inc (OHRP) Snapshot

Open
$7.27
Previous Close
$7.32
Day High
$7.42
Day Low
$7.19
52 Week High
03/17/14 - $20.00
52 Week Low
05/12/14 - $6.01
Market Cap
183.7M
Average Volume 10 Days
92.1K
EPS TTM
$-0.39
Shares Outstanding
24.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OHR PHARMACEUTICAL INC (OHRP)

ohr pharmaceutical inc (OHRP) Related Bloomberg News

View More Bloomberg News

ohr pharmaceutical inc (OHRP) Related Businessweek News

No Related Businessweek News Found

ohr pharmaceutical inc (OHRP) Details

OHR Pharmaceutical, Inc. operates as a biotechnology company. Its product line includes Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that inhibits vascular endothelial, platelet derived, and basic fibroblast growth factors for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. The company also offers OHR/AVR 118, a Phase IIa clinical trial product for the treatment of cancer cachexia. In addition, it owns various other compounds in earlier stages of development, including the PTP1b inhibitor trodusquemine and related analogs, which are in preclinical research stage. The company is headquartered in New York, New York.

2 Employees
Last Reported Date: 12/27/13

ohr pharmaceutical inc (OHRP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $162.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $130.6K
Compensation as of Fiscal Year 2013.

ohr pharmaceutical inc (OHRP) Key Developments

Ohr Pharmaceutical, Inc. - Special Call

To consider the key opinion leader analyst breakfast

Ohr Pharmaceutical, Inc. Launches Phase 3 Trials of Squalamine Eye Drops

Ohr Pharmaceuticals (OHRP) announced that it will begin Phase 3 trials in the first half of 2015 for Squalamine Eye Drops (OHR-102) in the treatment of wet age-related macular degeneration (wet AMD). The company planed a New Drug Application (NDA) following collection and analysis of the nine-month primary efficacy data. The trials are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent meeting marking the end of Phase 2. The FDA has agreed with Ohr on a nine-month primary efficacy endpoint based on the proportion of patients achieving a =3 line gain in visual acuity. The Phase 3 trials for Squalamine eye drops are being designed to measure the efficacy of combination therapy with OHR-102 eye drops plus Lucentis injections compared with Lucentis monotherapy.

Ohr Pharmaceutical Announces Successful End of Phase II Meeting with the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD

Ohr Pharmaceutical, Inc. announced details of the planned pivotal Phase III registration trials for Squalamine Eye Drops (OHR-102) in the treatment of wet age-related macular degeneration (wet AMD). The trials are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent 'end of Phase II" meeting. The FDA has agreed with Ohr on a 9 month primary efficacy endpoint based on the proportion of patients achieving a >=3 line gain in visual acuity. In the interim analysis of the ongoing Phase II IMPACT study, more than twice the proportion of patients achieved >=3 line gains in visual acuity at 9 months with the combination of OHR-102 eye drops and Lucentis(R) as compared to the Lucentis monotherapy group (overall p=0.025, classic lesions p=0.007). Two identical Phase III studies will be performed. The Company plans to initiate the Phase III trials in the first half of 2015 with the goal of submitting a New Drug Application (NDA) following collection and analysis of the 9 month primary efficacy data. The Phase III trials for Squalamine eye drops are being designed to measure the efficacy of combination therapy with OHR-102 eye drops plus Lucentis injections compared with Lucentis monotherapy at 9 months. All patients will be followed for safety for 2 years. The primary endpoint will be a measure of improvement in visual acuity, as defined by the proportion of patients achieving gains of >=3 lines or more on the early treatment diabetic retinopathy study chart. During the first year of the study, patients will be randomized 1:1 to receive monthly Lucentis plus OHR-102 (Squalamine eye drops) twice a day or Lucentis plus placebo. During the second year they will receive Lucentis PRN (as needed) plus OHR-102 or placebo twice a day.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OHRP:US $7.39 USD +0.07

OHRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OHRP.
View Industry Companies
 

Industry Analysis

OHRP

Industry Average

Valuation OHRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OHR PHARMACEUTICAL INC, please visit www.ohrpharmaceutical.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.